IRVINE, Calif., Aug. 4 /PRNewswire/ — OvaGene Oncology
Inc., a biotechnology company specializing in the
development and commercialization of personalized DNA-based
diagnostics for gynecologic cancer, is pleased to announce their
partnership with The Gynecologic Oncology Group (GOG) through the
Industry Collaboration Team (ICT) program. By becoming a
member of the ICT, OvaGene Oncology demonstrates its commitment to
building a strong partnership with the GOG research groups, namely
medical centers, universities, and pharmaceutical companies
dedicated to advancing the scientific and clinical knowledge of
gynecologic cancers.
OvaGene’s mission to improve the quality of life and survival
for gynecologic cancer patients is further enhanced by joining this
select group. The Industry Collaboration Team has a limited
membership and OvaGene is honored to have been given an opportunity
to become a member. By joining the ICT program, OvaGene will gain
direct access to oncology leaders and key decision makers in the
field gynecologic oncology. This will facilitate direct
communication with the cancer treating physicians about OvaGene’s
products and diagnostic research capabilities. The valuable
feedback provided can help accelerate the development of OvaGene’s
product pipeline by allowing the company to identify and address
unmet clinical needs.
“We are very pleased to be an ICT member,” said William Ricketts, Ph.D., Chief Scientific
Officer for OvaGene. “The GOG has one of the largest archived
and annotated gynecologic tumor banks. It is a privilege to
be given the opportunity to collaborate with the GOG as a member of
the ICT and potentially on studies focused to discover and validate
new molecular diagnostics. This will help us bring cl
‘/>”/>
